Muse Invent enables researchers not only to design dream molecules, but it also shows how to produce them in the lab
TOKYO, JAPAN and PRINCETON, NJ – 2014年12月9日 – Certara®, the leading global technology-enabled drug development and drug safety consultancy, today announced the launch in Japan of Muse® Invent, its molecular design workflow for the identification and optimization of lead drug candidates, which also possesses virtual synthetic chemistry capabilities. This new product enables researchers to create drug candidates with novel structures, scaffolds, or side-chains that meet multiple design objectives and are synthetically accessible. It will also describe the necessary synthesis pathway to create them.
“Our original Muse product was always popular because it permitted ‘outside of the box’ chemistry thinking; it allowed customers to generate new chemical ideas without being limited to molecules found in existing databases and product catalogs,” said Certara Chief Technology Officer Jonathan Feldmann. “But when customers became enamored with the new molecules they created in Muse, they wanted to know how to make them in the lab.”
Certara responded promptly to this customer feedback and began to develop Muse Invent.
Brian Masek, a product manager at Certara, added, “Muse Invent is one of the first products to build a bridge between the traditional worlds of molecular design and synthetic chemistry. In the past, design software would suggest and score ideas, while synthetic chemistry tools would help researchers to look up reactions; Muse Invent combines both design and synthesis capabilities in a single product. It enables researchers to generate drug design ideas that satisfy all their criteria for success.”
Certara currently has more than 200 clients in Japan, including all the top 20 Japanese pharmaceutical companies. Muse Invent will be deployed and supported by the Certara GK office in Tokyo, which was established in 2011.
Certara is the leading technology-enabled drug development and drug safety consultancy. Its customers include hundreds of biopharmaceutical companies around the globe, together with several regulatory agencies. Certara’s solutions, which span the discovery, preclinical and clinical stages of drug development, enable data-driven decisions, leading to more precisely designed trials with a reduced risk of failure and improved subject safety. For more information, visit www.certara.com.
Director, Enterprise Sales
Certara G.K., +81 (0)50 3786 9898
Teresa A. Bradford, 919-852-4644
Senior Director, Marketing
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions